Sino Biopharmaceutical Limited (FRA:SMZ1)

Germany flag Germany · Delayed Price · Currency is EUR
0.9700
-0.0226 (-2.28%)
Last updated: Sep 9, 2025, 5:51 PM CET
-2.28%
Market Cap17.44B
Revenue (ttm)3.63B
Net Income (ttm)460.14M
Shares Outn/a
EPS (ttm)0.03
PE Ratio37.90
Forward PE32.98
Dividend0.01 (1.03%)
Ex-Dividend DateAug 29, 2025
Volumen/a
Average Volume18,378
Open0.9494
Previous Close0.9926
Day's Range0.9494 - 0.9700
52-Week Range0.3392 - 0.9926
Betan/a
RSI69.20
Earnings DateAug 25, 2025

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules... [Read more]

Industry Pharmaceutical Preparations
Founded 2000
Employees 24,379
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol SMZ1
Full Company Profile

Financial Performance

In 2024, Sino Biopharmaceutical's revenue was 28.87 billion, an increase of 10.18% compared to the previous year's 26.20 billion. Earnings were 3.50 billion, an increase of 50.08%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.